Lineage Cell Therapeutics, Inc. (LCTX)
NYSEAMERICAN: LCTX · Real-Time Price · USD
0.4635
-0.0065 (-1.38%)
May 14, 2025, 3:07 PM - Market open
Lineage Cell Therapeutics Revenue
Lineage Cell Therapeutics had revenue of $1.50M in the quarter ending March 31, 2025, with 4.02% growth. This brings the company's revenue in the last twelve months to $9.56M, up 19.42% year-over-year. In the year 2024, Lineage Cell Therapeutics had annual revenue of $9.50M with 6.19% growth.
Revenue (ttm)
$9.56M
Revenue Growth
+19.42%
P/S Ratio
10.38
Revenue / Employee
$124,117
Employees
77
Market Cap
105.84M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 9.50M | 554.00K | 6.19% |
Dec 31, 2023 | 8.95M | -5.76M | -39.16% |
Dec 31, 2022 | 14.70M | 10.36M | 238.70% |
Dec 31, 2021 | 4.34M | 2.52M | 137.73% |
Dec 31, 2020 | 1.83M | -1.69M | -48.05% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
LCTX News
- 7 hours ago - Lineage to Present at 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC - Business Wire
- 21 hours ago - Lineage Cell Therapeutics, Inc. (LCTX) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 23 hours ago - Lineage Cell Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - Business Wire
- 2 days ago - RG6501 (OpRegen®) Phase 1/2a Clinical Study 36 Month Results to Be Featured at Clinical Trials at the Summit 2025 - Business Wire
- 13 days ago - Lineage Cell Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025 - Business Wire
- 22 days ago - Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 3rd Annual Spinal Cord Injury Investor Symposium - Business Wire
- 23 days ago - Lineage to Present at 2025 Eyecelerator Meeting Sponsored by the American Academy of Ophthalmology (AAO) - Business Wire
- 2 months ago - Lineage Cell Therapeutics, Inc. (LCTX) Q4 2024 Earnings Call Transcript - Seeking Alpha